Imperial Capital Lowers PT on Amylin Pharmaceuticals to $7.50

Symbols: AMLN
Share

Imperial Capital has lowered the price target on Amylin Pharmaceuticals (NASDAQ: AMLN) from $10 to $7.50 and maintains its Underperform rating.


 
 
< Previous
UPDATE: Jefferies Raises PT to $60 on MICROS Systems
Next >
UPDATE: Morgan Stanley Downgrades Teva Pharmaceuticals to Equal-Weight
Share
Printer-friendly version
Send to friend
We're Loving

Benzinga's Premium Memberships

Benzinga's News Delivered Free

Brain Trust